Diagnostic and prognostic value of nested polymerase chain reaction in the post-transplant reactivation of cytomegalovirus (CMV) infection  by Singh, Sarman et al.
Abstracts of the 12th ISIIH 2325 
doses up to 100 mg per day with second drug therapy of 
azathioprine or alternatively cyclophosphamide. After 
the transfer to our hospital a plethora of laboratory 
studies for rheumatologic, inflammatory, and infectious 
processes where obtained and except for a very modest 
decrease in C4 all where normal. A further contrast 
enhanced MRT of the brain showed extensive right- 
sided white matter disease with significant extension into 
the left hemisphere. An HIV ELISA, a CD4 count, and 
a JC virus PCR were obtained.The ELISA was negative; 
but the CD4 count was 52 and JCV-VL was 2888 
copies/ml (normal ~80). An exhaustive literature search 
revealed minimal therapeutic options for the JC virus 
infection, and the patient was discharge to hospice in the 
care of her physician on a suggested regimen of 
a prednisone taper, and hopefully therapeutic alpha- 
interferon and cidofovir treatment. As of February 2002 
the patient remains bed bound. 
This devastating case of JC virus infection illustrates 
the confounding diagnostic dilemmas frequently encoun- 
tered by practitioners. In this instance a consistent 
explanation is found with the realization that the patient 
probably suffers from advanced iatrogenic immuno- 
suppression and the resultant possible opportunistic in- 
fections. 
Valacyclovir for the prevention of CMV disease after 
renal transplantation: A 5year follow-up 
*Hans-H. Neumayer, Jean-Paul Squifflet, 
David Lowance, Christophe M. Legendre 
*Department of Nephrology, University Hospital 
Charit&, Berlin, Germany 
Objective: Valacyclovir 2g four times daily for 90 days 
has been shown (Lowance et al., NEJM 1999: 340:1462- 
70) to reduce the incidence of cytomegalovirus (CMV) 
infection and disease and acute graft rejection (GR) at 
six months vs placebo after renal transplantation. Among 
the CMV seropositive patients (R+) the incidence of 
CMV disease was reduced from 6% to 1% and there was 
a reduction in biopsy confirmed acute GR from 36% 
to 30%. CMV disease was significantly reduced in the 
donor-positive recipient-negative (D+R-) group from 
45% to 16% and rate of biopsy confirmed acute GR 
from 52% to 26% compared to placebo. This retro- 
spective review of patients’ medical notes was designed 
to assess whether the benefits extend to increased graft 
function and survival during 5 years follow-up. 
Methods: Data were available for 449 of the 616 patients 
enrolled in the original study, P66/H73-012. The primary 
population for analysis was the ITT population of all 
patients randomised in the original study. The primary 
endpoint was time to allograft failure up to 5 years post- 
transplant. Rates of acute GR, chronic GR, CMV disease 
and survival were secondary endpoints. 
Results: No significant treatment difference was 
observed for time to allograft failure in either the R+ or 
D+R- patients although the benefits in preventing 
CMV disease and acute GR are still evident at 5 years. 
fR+) (D+R-J 
Val PBO Val PBO 
Endpoint n=204 n=204 HR n=106 n=l02 HR 
Allograft failure 28 23 1.29 25 24 0.91 
Acute GRa 39 41 0.91 36 55 0.52* 
Chronic GRa 28 16 1.86** 24 30 0.67 
fvavkeaseb 2 8 11 6 0.28* 6  15 7 43 16 0.22* .43 
*Statistically significant in favour of valaciclovir. **Statistically significant 
in favour of placebo. 
aBiopsy confirmed graft rejection. bLaboratory confirmed graft rejection. 
Conclusions: The benefit of 90 days treatment with 
valacyclovir in preventing acute GR in D+R- patients 
is still apparent at 5 years post-transplant. A trend to 
increased patient survival with valacyclovir in the high- 
risk D+R- patients is noted. 
Diagnostic and prognostic value of nested polymerase 
chain reaction in the post-transplant reactivation of 
cytomegalovirus (CMV) infection 
Sarman Singh, Niti Singh, R. Sivakumar 
Department of Laboratory Medicine, All India Institute 
of Medical Sciences, New Delhi (India) 
Confirmatory diagnosis of reactivated human cyto- 
megalovirus (HCMV) infections can only be made by 
culturing the virus in cell culture, or alternatively by 
detecting its antigen or its nucleic acids using amplifica- 
tion techniques. It is necessary because presence of IgM 
antibodies is not a reliable method of viral replication 
and does not correlate well with disease manifestations. 
Detection of HCMV DNA in clinical specimens is 
considered a cornerstone in the diagnosis of CMV 
disease. For amplifying the specific CMV DNA nested 
polymerase chain reaction (nPCR) is reported to higher 
specificity. Therefore, we carried out a study to compare 
the usefulness of nested PCR vis-a-vis commonly used 
u-capture enzyme linked immunosorbent assay (mac- 
ELISA) in renal and bone marrow transplant patients 
with clinical manifestations suggestive of post-transplant 
CMV reactivation. A total of 49 blood specimens were 
collected from 19-bone marrow and 30 renal transplant 
patients. All the samples were subjected to IgG, IgM 
ELISA and Nested PCR assay. The age of our patients 
ranged from 18 to 50 years (mean age 32+17). Most of 
our patients were males (44) while only 5 were females. 
All of the 49 patients were found positive for anti-CMV 
IgG antibodies (100%) and only 22.45% were IgM 
positive. Where as, nPCR was positive in 69.38% of 
cases. All PCR positive patients responded to anti-CMV 
therapy. Hence, this study concluded that the nested 
PCR is more sensitive as well as specific in symptomatic 
transplant cases and must be carried out at all transplant 
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centers of India. This will not only help in better 
management of the patients but also the approach is cost 
effective in long run as against the myth that such tests 
are unaffordable for developing world. 
Respiratory virus infections after bone marrow 
transplant (BMT) in SPo Paula, Brazil 
C. M. Machado, L. S Vilas Boas, A. VA. Mendes, 
M. Z! M. Santos, D. Sturaro, C. S. Pannuti 
BMT Program, Discipline of Hematology and Virology 
Laboratory, Institute of Tropical Medicine*, University 
of Sao Paul0 Medical School, Brazil 
Respiratory viruses (RV) are a frequent cause of severe 
respiratory disease in BMT recipients. Few clinical and 
epidemiological data of RV infections are available in 
immunocompromised patients in South America. We 
conducted a prospective trial from April 2001 to January 
2002 to evaluate the frequency of respiratory viruses in 
BMT recipients. Nasal washes (NW) were collected in 
all patients with symptoms of upper respiratory tract 
infection (URI). Direct immunofluorescence assay 
(DAKO) was performed for antigen detection of RSV, 
influenza (Flu) A and B, adenovirus and parainfluenza 
(Paraflu) virus. Patients with established RSV pneu- 
monia and patients with RSV-URI infection before 
engraftment or those with acute GvHD grade 111 
received aerosolized ribavirin. Oseltamivir was given to 
all patients with influenza. One hundred ninety seven 
patients had 314 episodes of URI during the study 
period (mean 1,6 episodes per patient). The mean 
number of NW taken was 3,14 (1 to 16) per patient. 
Sixty-eight patients (34.5%) tested positive: RSV was 
detected in 15 patients (22%); Flu B in 18 (26.4%) Flu 
A in 14 (20.5%) and Paraflu in 4 (5.8%). Most frequent 
virus associations were RSV+Flu A, Flu A+Flu B and 
RSV+Flu B (5.8%; 5.8% and 4.4% respectively). The 
remaining 6 patients (8.8%) had other RV associations. 
RSV pneumonia developed in 12 of the 25 patients 
(48%) with RSV-URI. RSV related death was observed 
in 1 patient with pneumonia (8.3%). Flu B pneumonia 
was diagnosed in one patient (3.5%). Similarly to 
developed countries, RSV infections occurred during fall 
and early winter. Influenza viruses peaked in winter- 
spring months. Pre-emptive therapy with aerosolized 
ribavirin and oseltamivir probably contributed to the 
decreased rates of RSV related deaths and influenza 
pneumonia observed in the present study. 
Association of simian virus 40 (SV40) with pediatric 
renal disease 
J. A. Vanchiere,*A. S. Kale, Z. S. White, G. J Demmler, 
and J. S. Butel 
*Baylor College of Medicine, Departments of Pediatrics 
and Molecular Virology and Microbiology 
The polyomaviruses (BKV, JCV, and SV40) are 
ubiquitous agents that cause latent infection of the 
kidney with intermittent excretion in immune com- 
petent hosts and manifest disease during immune 
suppression. BKV causes nephropathy in adult renal 
transplant patients, and JCV is commonly found in the 
urine of healthy adults. Little is known about 
polyomavirus infection in pediatric patients with renal 
disease, although SV40 has been associated with 
pediatric renal transplantation by serologic testing and 
by direct detection of SV40 DNA in biopsy material. 
To test the hypothesis that polyomaviruses may be 
associated with pediatric renal disease, we enrolled 
children with NS (n=50) or immune compromise (HIV 
infection, acute lymphocytic leukemia or heart trans- 
plantation, n=36) in a prospective study of poly- 
omavirus infection as determined by polyomavirus PCR 
using buffy coat- and urine pellet-derived DNA samples, 
followed by virus-specific oligonucleotide hybridization. 
For comparison, we tested archival DNA samples from 
buffy coat specimens collected by the Diagnostic 
Virology Laboratory at Texas Children’s Hospital. 
There was no difference in the urinary excretion of 
polyomaviruses in total (JC virus, BK virus, or SV40), 
being present in 18 of 59 samples (30.5%) from children 
with NS and in 4 of 22 samples (18.2%) from children of 
the immune-compromised groups (p=O.43). Of 35 
children with renal disease, BKV, JCV, and SV40 were 
detected in the urine of 6,10 and 7 children, respectively. 
Among 15 children with immune compromise, BKV, 
JCV, and SV40 were detected in the urine of 2,2, and 0 
patients, respectively. Only SV40 excretion was found to 
be associated with renal disease (p=O.O3). From buffy 
coat samples, 8 of 26 children with renal disease were 
positive for SV40, whereas none contained detectable 
JCV or BKV DNA. Several children were identified 
with concurrent SV40 viremia and viruria. In contrast, 
none of 136 archival DNA samples from 86 children 
were positive for SV40 sequences (p<O.OOl). 
Taken together, these data suggest an association of 
SV40 polyomavirus infection with pediatric renal 
disease. Further studies are required to delineate the 
pathophysiologic and prognostic significance of SV40 
infection in children with renal disease and after renal 
transplantation. 
Randomized controlled trial of oral ganciclovir 
versus intravenous ganciclovir for long-term 
prophylaxis of cytomegalovirus (CMV) disease 
in CMV-seronegative liver transplant recipients 
willi CMV-seropositive donors 
D. Winston and R. W Busuttil 
*UCLA Medical Center, Los Angeles, CA, USA 
For high-risk CMV-seronegative liver transplant 
recipients with CMV-seropositive donors, 100 days of 
post-transplant intravenous (IV) ganciclovir has been 
the most effective regimen for prophylaxis of CMV 
disease but is limited by the need for prolonged IV 
